Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why MyoKardia Stock Is on Fire Today

TheMotleyFool

0 0

Why MyoKardia Stock Is on Fire TodayPhoto, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

MyoKardia (NASDAQ: MYOK), a clinical-stage biotech, is having a tremendous Monday morning. The drugmaker's shares were up by an eye-popping 65% on sky-high volume as of 9:59 a.m. EDT on Monday.

The spark? Ahead of the opening bell, MyoKardia announced that its experimental obstructive hypertrophic cardiomyopathy drug mavacamten met all of its primary and secondary endpoints in a late-stage trial. Equally as important, mavacamten was also reportedly well tolerated in the study.

Image source: Getty Images.

Source Fool.com

Like: 0

MYOK

Share